MDG-2021

N/A

Report date: 2023/09/19 14:52:24

Base Information

Drug NameMDG-2021
Drug Alias NameMDG-2021MDG2021
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12D modulators
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedigene Ag
China Registration ClassN/A

Develop Information

Active CompaniesMedigene Ag
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A